<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="./PMC5094061/results/search/funders/results.xml">
  <result pre="CPA was used Endoxan infusion Ⓡ 500 mg manufactured by" exact="Shionogi" post="&amp;amp; Co., Ltd. (Osaka, Japan). As for the CPA"/>
  <result pre="determined using HPLC with ultraviolet detection (Hitachi D-2000 Elite system;" exact="Hitachi" post="High-Technologies Co., Ltd., Tokyo, Japan) following a previous protocol"/>
  <result pre="injected into a column (LiChrosorb® RP-8; 5 μm, 2.1 × 150 mm," exact="Merck" post="KGaA, Darmstadt, Germany) maintained at 40 °C as a"/>
  <result pre="in the cancer pharmacotherapy. Editors Japanese Society of Cancer Nursing," exact="Japanese Society of Medical Oncology," post="Japanese Society of Pharmaceutical Oncology. Tokyo: KANEHARA &amp;amp; CO.,"/>
 </snippets>
</snippetsTree>
